SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third quarter 2025 financial results on Tuesday, November 4, 2025, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live ...

Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth "Neurocrine's third quarter commercial results highlight the meaningful impact that INGREZZA and CRENESSITY are having on patients' lives. INGREZZA achieved another record quarter in new patient starts and total prescriptions, further demonstrating continued unmet need within the tardive dyskinesia and Huntington's chorea market. CRENESSITY's strong launch reflects its status as a first-in-class therapy that is changing ...

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ: SBFM ) is quickly establishing which side of that line it's on. ...

Going into this search the Power Lunch team expected most of the stocks would be A.I. related. We were wrong.San Francisco is one of the world's great cities. Culture, food, beauty and business power the peninsula. Yes, the city has problems, but finding great stocks to invest in from the area is not one of them, if you know where to look.Ahead of this special programming, I sought to find the companies based in the city that were making investors the most money this year. Just as the city itself defies exp ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy. On October 20, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on PTC Therapeutics, Inc. (NASDAQ:PTCT), lifting the price target on the stock to $87 from $76. PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential The analyst cited the solid initial demand for Sephience, which is the company’s newly approved treatment. A notable inter ...

Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Fye associated the rating with the company’s market position and cur ...

Wall Street expects a year-over-year increase in earnings on lower revenues when PTC Therapeutics (PTCT) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 4, might help the stock move higher if these key numbers are better than e ...

Alkermes (NasdaqGS:ALKS) Q3 2025 Earnings Call October 28, 2025 08:00 AM ET Company ParticipantsTodd Nichols - Chief Commercial OfficerRichard Pops - CEOChi Eze - Perfomance ManagerJoshua Reid - CFOPaul Matisse - Managing DirectorDouglas Tsao - Managing Director of Equity ResearchLeonid Timoshev - Head of Healthcare ResearchManoj Radder - VPAmi Fadia - Stock analystSandra Coombs - SVP, Investor Relations and Corporate AffairsConference Call ParticipantsNone - AnalystNone - AnalystNone - AnalystJoseph Thome ...

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, announces a landmark development for global healthcare innovation, His Highness Sheikh Nahyan bin Zayed Al Nahyan, Chairman of the Zayed Charitable and Humanitarian Foundation, will formally assume the role of Executive Chairman of Nu ...

Alkermes (NasdaqGS:ALKS) Q3 2025 Earnings Call October 28, 2025 08:00 AM ET Speaker6Greetings. Welcome to the Alkermes third quarter 2025 financial results conference call. My name is Rob, and I'll be your operator for today's call. All participant lines will be placed on mute to prevent background noise. If you should require operator assistance during the call, please press star zero from your telephone keypad. Please note that this conference is being recorded. I will now turn the call over to Sandra Coo ...